PF-00477736 + gemcitabine

PF-00477736 + gemcitabine is an investigational anti-cancer combination therapy pairing PF-00477736, a potent, selective, ATP-competitive small-molecule inhibitor of checkpoint kinase 1 (Chk1), with gemcitabine, a nucleoside analogue chemotherapeutic agent. PF-00477736 inhibits Chk1 (and, to a lesser extent, Chk2), breaching DNA damage checkpoints and abrogating gemcitabine-induced S-phase cell-cycle arrest, thereby forcing damaged p53-defective tumor cells into mitotic catastrophe and apoptosis[1][2][3][4]. The combination selectively potentiates cytotoxic effects in p53-deficient cancer cells and shows minimal toxicity in normal p53-competent cells. PF-00477736 enhances gemcitabine’s antitumor activity in vitro and in vivo, especially in advanced solid tumors and acute lymphoblastic leukemia.